Methods for reducing CD36 expression

Details Methods for reducing CD36 expression Methods for reducing CD36 expression

2006-09-18

2009-06-02

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600

Reexamination Certificate

active

07541340

ABSTRACT:
The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pmis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2ais the largest number that is less than or equal to pt−1, except that when a is 1, ptmay also be 1.

REFERENCES:
patent: 5312899 (1994-05-01), Schiller
patent: 5602100 (1997-02-01), Brown et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5885958 (1999-03-01), Zadina et al.
patent: 5993848 (1999-11-01), Suzuki et al.
patent: 5994372 (1999-11-01), Yaksh
patent: 6221355 (2001-04-01), Dowdy
patent: 6268398 (2001-07-01), Ghosh et al.
patent: 6503713 (2003-01-01), Rana
patent: 6703483 (2004-03-01), Schiller
patent: 6759520 (2004-07-01), Carr et al.
patent: 6900178 (2005-05-01), Oeltgen et al.
patent: 2004/0248808 (2004-12-01), Szeto et al.
patent: 2005/0096333 (2005-05-01), Dugar et al.
patent: 2005/0192215 (2005-09-01), Ghosh et al.
patent: 2361364 (2000-09-01), None
patent: WO9522557 (1995-08-01), None
patent: WO0055189 (2000-09-01), None
patent: WOO205748 (2002-01-01), None
patent: WO 2004/070054 (2004-08-01), None
Clapp III, et al. “Cardiovascular and Metabolic Responses to Two Receptor-Selective Opioid Agonists in Pregnant Sheep”, American Journal of Obstetrics and Gynecology, vol. 178, No. 2 (Feb. 1998) pp. 397-401.
Holsey, et al. “Cardiovascular Effects of a μ-Selective Opioid Agonist (Tyrosine-D-Arginine-Phenylalanine-Lysine-NH2) in Fetal Sheep: Sites and Mechanisms of Action”, J. Obstet. Gynecol., vol. 180, No. 5 (May 1999) pp. 1127-1130.
Kett, et al. “Baroreflex-Mediated Bradycardia but Not Tachycardia is Blunted Peripherally by Intravenous μ-opioid Agonists”, Am. J. Obstet. Gynecol., vol. 178, No. 5 (May 1998) pp. 950-955.
Neilan, et al. “Pharmacological Characterization of the Dermorphin Analog [Dmt1]DALDA, a Highly Potent and Selective μ -Opioid Peptide”, European Journal of Pharmacology, vol. 419, Issue 1 (2001) 15-23.
Omoniyi, et al. “A Peripheral Site of Action for the Attenuation of Baroreflex-Mediated Bradycardia by Intravenous μ -Opioid Agonists”, Journal of Cardiovascular Pharmacology TM, vol. 35, No. 2 (2000) pp. 269-274.
Schiller, et al. “Dermorphin Analogues Carrying an Increased Positive Net Charge in Their “Message”Domain Display Extremely High μOpioid Receptor Selectivity”, Journal of Medicinal Chemistry, vol. 32, No. 3 (1989) pp. 698-703.
Schiller, et al. “Synthesis and In Vitro Opioid Activity Profiles of DALDA Analogues”, European Journal of Medicinal Chemistry, vol. 35, Issue 10 (Oct. 2000) pp. 895-901.
Shimoyama, et al. “Antinociceptive and Respiratory Effects of Intrathecal H-3-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1]DALDA”, The Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 1 (Apr. 2001) pp. 364-371.
Szeto, et al. “In Vivo Disposition of Dermorphin Analog (DALDA) in Nonpregnant and Pregnant Sheep”, The Journal of Pharmacology and Experimental Therapeutics, vol. 284, No. 1 (1998) pp. 61-65.
Szeto, et al. “Respiratory Depression After Intravenous Administration of δ -Selective Opioid Peptide Analogs”, Peptides, vol. 20 (1999) pp. 101-105.
Szeto, et al. “Mu-Opioid Receptor Densensitization and Resensitization In Vivo”, International Narcotics Research Conference, Poster Abstracts, Monday (1999) Mon19, p. 5.
Szeto, et al. “In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists”, The Journal of Pharmacology and Experimental Therapeutics, vol. 298, No. 1 (Jul. 2001) pp. 57-61.
Wu, et al. “Myocardial Protective Effect of Mu Opioid Agonists”, International Narcotics Research Conference, Poster Abstracts, Sunday (1999) Sun59, p. 15.
Broekemeier, et al., “Inhibition of the Mitochondrial Permeability Transition by Cyclosporin A during Long Time Frame Experiments: Relationship between Pore Opening and the Activity of Mitochondrial Phospholipases”, Biochemistry 1995, 34:16440-16449.
Wu, et al., “A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning”, Am J Physiol Heart Circ Physiol 2002, 283:H783-H791.
Schiller, et al., “Opioid peptide analogs with novel activity profiles as potential therapeutic agents for use in analgesia”, Peptide Science—Present and Future, Proc. Int. Pept. Symp., 1st, Y. Shimonishi (ed), 1999, pp. 665-669.
Schiller, et al., “Opioid Peptide Analogs With Novel Activity Profiles as Potential Therapeutic Agents For Use in Analgesia”, First International Peptide Symposium, Program & Abstracts, Nov. 30-Dec. 5, 1997, Kyoto, Japan, 0-36, p. 77.
Zhao, et al., “Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury”, J. Biol. Chem., Aug. 2004, vol. 279, No. 33, pp. 34682-34690.
File Medline on STN An No. 2005478947. Simmons, Zachary. “Management Strategies for Patients with Amyotrophic Lateral Sclerosis from Diagnosis Through Death”, The Neurologist (Sep. 2005), vol. 11, No. 5, pp. 257-270. Abstract only.
Azzouz, Mimoun, “Gene Therapy for ALS: Progress and Prospects” Biochemical et Biophysica Acta (2006), vol. 1762 pp. 112-1127.
Margolis, et al. “Diagnosis of Huntington Disease”, Clinical Chemistry, vol. 49, No. 10 pp. 1726-1732 (2003).
Korczyn, et al. “Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease”, Drugs vol. 62, No. 5, pp. 775-786. 2002.
Sriram, et al., “Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis”, Ann. Neurol. vol. 58, pp. 939-945, 2005.
Steinman, et al., “How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multiple Sclerosis”, Ann Neurol. vol. 60, pp. 12-21. 2006.
Citron, Martin, “Alzheimer's Disease: Treatments in Discovery and Development”, Nature Neuroscience Supplement. vol. 5 pp. 1055-1057. Nov. 2002.
Patel, et al., “Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review”, J. Geriatr. Psychiatry Neurol. vol. 8. pp. 81-95. 1995.
Zadina J. et al., “A Potent and Selective Endogeneous Agonist for the Mu-Opiate Receptor”, Nature, Nature Publishing Group, London, GB, vol. 386, Apr. 3, 1997, pp. 499-502, XP002072008.
Spetea, Mariana et al., “Interaction of agonist peptide (3H) Tyr-D-Ala-Phe-Phe-NH2 with mu-opioid receptor in rat brain and CHO-mu/1 cell line”, Peptides (New York), vol. 19, No. 6, 1998, pp. 1091-1098, XP002410285.
Dooley, C T et al., “Selective ligands for the mu, delta and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library”, Journal of Biological Chemistry, American Society of Biochemistry and Molecular Biology, Birmingham, US, vol. 273, No. 30, July 24, 1998, pp. 18848-18856 XP002100725.
Schiller, P.W. et al., “Opioid peptide analogs with novel activity profiles as potential therapeutic agents for use in analgesia”, STN CAPLUS, No. 132:102403, 1997, XP002933635.
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”, 2000, Genome Research 10:398-400.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, 2000, Trends in Biotech. 18(1):34-39.
Doerks et al., “

Affiliated with

Also associated with

Rating

Methods for reducing CD36 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for reducing CD36 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing CD36 expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4091391